Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo

Molecular regulation of autophagy machinery by mTOR‐dependent and ‐independent pathways

(2020) Md. Abdul Alim Al‐Bari et al.   Annals of the New York Academy of Sciences

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

(2020) Steven P. Treon et al.   BLOOD

BTK inhibitors in cancer patients with COVID19: "The winner will be the one who controls that chaos" (Napoleon Bonaparte)

(2020) Elise A. Chong et al.   CLINICAL CANCER RESEARCH

A Fast and Clean BTK Inhibitor

(2020) Ronen Gabizon et al.   JOURNAL OF MEDICINAL CHEMISTRY

Anti-hyperglycemic activity of myricetin, through inhibition of DPP-4 and enhanced GLP-1 levels, is attenuated by co-ingestion with lectin-rich protein

(2020) Nanjaiah Lalitha et al.   PLoS One

On the Alert for Cytokine Storm: Immunopathology in COVID ‐19

(2020) Lauren A. Henderson et al.   Arthritis & Rheumatology

Effects of Hot-Water Extract from Vine Tea (Ampelopsis grossedentata) on Acrylamide Formation, Quality and Consumer Acceptability of Bread

(2020) Qian Ma et al.   Foods

Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial

(2020) Fabian Knörr et al.   JOURNAL OF CLINICAL ONCOLOGY

Potential of Flavonoid-Inspired Phytomedicines against COVID-19

(2020) Wilfred Ngwa et al.   MOLECULES

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

(2020) Mark Roschewski et al.   Science Immunology

Pathophysiology of COVID-19-associated acute respiratory distress syndrome

(2020) Luigi Camporota et al.   Lancet Respiratory Medicine

Myricetin: A review of the most recent research

(2020) Xiaominting Song et al.   BIOMEDICINE & PHARMACOTHERAPY

Management of adverse effects/toxicity of ibrutinib

(2019) Semra Paydas   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Interaction between phytotherapy and oral anticancer agents: prospective study and literature review

(2019) Anne-Laure Clairet et al.   MEDICAL ONCOLOGY

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

(2019) Richard D. Caldwell et al.   JOURNAL OF MEDICINAL CHEMISTRY

Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases

(2019) Kata P. Szilveszter et al.   Frontiers in Immunology

Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma

(2018) Kieron Dunleavy et al.   CANCER TREATMENT REVIEWS

Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer

(2018) Tilly Varughese et al.   CLINICAL INFECTIOUS DISEASES

The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review

(2018) Chengyuan Liang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery

(2018) Nicholas Thomford et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cell-of-origin in diffuse large B-cell lymphoma: findings from the UK's population-based Haematological Malignancy Research Network

(2018) Daniel Painter et al.   BRITISH JOURNAL OF HAEMATOLOGY

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

(2017) Jennifer A. Woyach et al.   JOURNAL OF CLINICAL ONCOLOGY

Non-Hodgkin lymphoma

(2017) James O Armitage et al.   LANCET

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining “Actionability” of a Molecular Lesion and Patient Management Support

(2017) Young Kwang Chae et al.   MOLECULAR CANCER THERAPEUTICS

Multifaceted Roles of GSK-3 in Cancer and Autophagy-Related Diseases

(2017) Romina Mancinelli et al.   Oxidative Medicine and Cellular Longevity

2016 US lymphoid malignancy statistics by World Health Organization subtypes

(2016) Lauren R. Teras et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Second-generation inhibitors of Bruton tyrosine kinase

(2016) Jingjing Wu et al.   Journal of Hematology & Oncology

Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms

(2016) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Myricetin: A Dietary Molecule with Diverse Biological Activities

(2016) Deepak Semwal et al.   Nutrients

Diffuse large B-cell lymphoma: R-CHOP failure--what to do?

(2016) B. Coiffier et al.   Hematology-American Society of Hematology Education Program

Molecular modeling studies on series of Btk inhibitors using docking, structure-based 3D-QSAR and molecular dynamics simulation: a combined approach

(2015) Pavithra K. Balasubramanian et al.   ARCHIVES OF PHARMACAL RESEARCH

Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2

(2014) Daruka Mahadevan et al.   PLoS One

Ibrutinib and novel BTK inhibitors in clinical development

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biological Activities of Extracts from Chinese Bayberry (Myrica rubra Sieb. et Zucc.): A Review

(2013) Chongde Sun et al.   PLANT FOODS FOR HUMAN NUTRITION

Non-Hodgkin lymphoma

(2012) Kate R Shankland et al.   LANCET

Target molecules of food phytochemicals: Food science bound for the next dimension

(2012) Akira Murakami et al.   Food & Function